β-Adrenoreceptor agonists in the management of pain associated with renal colic: a systematic review

Andrew John Tabner, Graham David Johnson, Apostolos Fakis, Jane Surtees, Robert Iain Lennon, Andrew John Tabner, Graham David Johnson, Apostolos Fakis, Jane Surtees, Robert Iain Lennon

Abstract

Objectives: To determine whether β-adrenoreceptor agonists are effective analgesics for patients with renal colic through a systematic review of the literature.

Setting: Adult emergency departments or acute assessment units.

Participants: Human participants with proven or suspected renal colic.

Interventions: β-adrenoreceptor agonists.

Outcome measures: Primary: level of pain at 30 min following administration of the β-agonist. Secondary: level of pain at various time points following β-agonist administration; length of hospital stay; analgesic requirement; stone presence, size and position; degree of hydronephrosis.

Results: 256 records were screened and 4 identified for full-text review. No articles met the inclusion criteria.

Conclusions and implications: There is no evidence to support or refute the proposed use of β-agonists for analgesia in patients with renal colic. Given the biological plausibility and existing literature base, clinical trials investigating the use of β-adrenoreceptor agonists in the acute setting for treatment of the pain associated with renal colic are recommended.

Trial registration number: CRD42015016266.

Keywords: ACCIDENT & EMERGENCY MEDICINE; PAIN MANAGEMENT; UROLOGY.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
PRISMA flow diagram demonstrating record handling during the systematic review.

References

    1. Curhan GC. Epidemiology of stone disease. Urol Clin North Am 2007;34:287–93. 10.1016/j.ucl.2007.04.003
    1. Bultitude M, Rees J. Management of renal colic. BMJ 2012;345:e5499 10.1136/bmj.e5499
    1. Davenport K, Waine E. The role of non-steroidal anti-inflammatory drugs in renal colic. Pharmaceuticals 2010;3:1304–10. 10.3390/ph3051304
    1. Holdgate A, Pollock T. Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic. Cochrane Database Syst Rev 2004;(1):CD004137 10.1002/14651858.CD004137.pub2
    1. Electronic Medicines Compendium. Summary of product characteristics: Ventolin 0.5mg in 1ml solution for injection. (cited 23 January 2015).
    1. Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press, 2015. (cited 10 January 2015).
    1. Malin JMJ, Deane RF, Boyarsky S. Characterisation of adrenergic receptors in human ureter. Br J Urol 1970;42:171–4. 10.1111/j.1464-410X.1970.tb10018.x
    1. Campschroer T, Zhu Y, Duijvesz D et al. . Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database Syst Rev 2014;(4):CD008509 10.1002/14651858.CD008509.pub2
    1. Matsumoto R, Otsuka A, Suzuki T et al. . Expression and functional role of β3-adrenoceptors in the human ureter. Int J Urol 2013;20:1007–14. 10.1111/iju.12093
    1. Mudraia IS, Kirpatovskĭ VI. [Adrenergic regulation of the contractility of the human and canine ureters]. Biull Eksp Biol Med 1992;113:363–5.
    1. Park YC, Tomiyama Y, Hayakawa K et al. . Existence of a beta3-adrenoceptro and its functional role in the human ureter. J Urol 2000;164:1364–70. 10.1016/S0022-5347(05)67200-X
    1. Tomiyama Y, Murakami M, Hayakawa K et al. . Pharmacological profile of KUL-7211, a selective beta-adrenoceptor agonist, in isolated ureteral smooth muscle. J Pharmacol Sci 2003;92:411–19. 10.1254/jphs.92.411
    1. Jung HU, Frimodt-Møller PC, Osther PJ et al. . Pharmacological effect on pyeloureteric dynamics with a clinical perspective: a review of the literature. Urol Res 2006;34:341–50. 10.1007/s00240-006-0069-x
    1. Rose JG, Gillenwater JY. The effect of adrenergic and cholinergic agents and their blockers upon ureteral activity. Invest Urol 1974;11:439–51.
    1. McLeod DG, Reynolds DG, Swan KG. Adrenergic mechanisms in the canine ureter. Am J Physiol 1973;224:1054–8.
    1. Kondo S, Morita T, Saeki H et al. . Effects of autonomic drugs on in vivo recording of electromyograms of canine renal pelvis and ureter. Urol Int 1985;40:260–6. 10.1159/000281095
    1. Morita T, Suzuki T, Kondo S et al. . Relationship between pelviureteral peristaltic frequency and urine flow change evoked by autonomic drug administration. Tohoku J Exp Med 1985;146:265–71. 10.1620/tjem.146.265
    1. Danuser H, Weiss R, Abel D et al. . Systemic and topical drug administration in the pig ureter: effect of phosphodiesterase inhibitors alpha1, beta and beta2-adrenergic receptor agonists and antagonists on the frequency and amplitude of ureteral contractions. J Urol 2001;166:714–20. 10.1016/S0022-5347(05)66049-1
    1. Jung H, Nørby B, Frimodt-Møller PC et al. . Endoluminal isoproterenol irrigation decreases renal pelvic pressure during flexible ureterorenoscopy: a clinical randomized, controlled study. Eur Urol 2008;54:1404–13. 10.1016/j.eururo.2008.03.092
    1. Wanajo I, Tomiyama Y, Tadachi M et al. . The potency of KUL-7211, a selective ureteral relaxant, in isolated canine ureter: comparison with various spasmolytics. Urol Res 2005;33:409–14. 10.1007/s00240-005-0475-5
    1. Wanajo I, Tomiyama Y, Yamazaki Y et al. . Ureteral selectivity of intravenous β-adrenoceptor agonists in pig model of acute ureteral obstruction: comparison of KUL-7211, a selective β2/β3 agonist, with isoproterenol, terbutaline, and CL-316243. Urology 2011;77:1266.e1–6 10.1016/j.urology.2010.12.045
    1. Morgan DJ, Paull JD, Richmond BH et al. . Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol 1986;22:587–93. 10.1111/j.1365-2125.1986.tb02939.x
    1. National Institute for Health Research. UK Clinical Trials Gateway. (accessed 17 Feb 2015).
    1. National Institute for Health Research. Clinical Research Network Portfolio.
    1. U.S. National Institutes of Health. . (accessed 17 Feb 2015).
    1. Aronson JK, Hauben M. Anecdotes that provide definitive evidence. Br Med J 2006;333:1267–9. 10.1136/bmj.39036.666389.94
    1. Erickson SB, Lieske JC. Medical management. Clin Rev Bone Miner Metab 2004;2:237–51. 10.1385/BMM:2:3:237
    1. Helviz Y, Hersch M, Shmuelevitz L et al. . Bad to worse. Am J Med 2011;124:215–17. 10.1016/j.amjmed.2010.11.007
    1. Reed M. Outlook: clinical trials. Pharm Times 2010;76(12). (accessed 17 Feb 2015).
    1. Pickard R, Starr K, MacLennan G et al. . Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. Lancet 2015;386:341–9. 10.1016/S0140-6736(15)60933-3
    1. Price AH, Clissold SP. Salbutamol in the 1980s. A reappraisal of its clinical efficacy . Drugs 1989;38:77–122. 10.2165/00003495-198938010-00004
    1. Peters HJ, Eckstein W. Possible pharmacological means of treating renal colic. Urol Res 1975;3:55–9. 10.1007/BF00256182

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe